Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...
Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...
Zacks Investment Research on MSN23h
Here's Why Halozyme Therapeutics (HALO) is a Strong Value StockIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...
AbbVie has expanded the availability of SKYRIZI in Canada for ulcerative colitis, strengthening its presence in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback